JUN 5, 2026

Medtronic expands its Acute Care & Monitoring portfolio in Europe with a distribution agreement for the Argos™* cardiac output monitor

With its advanced multi-beat haemodynamic algorithm, the Argos™* monitor expands parameters in the Medtronic perioperative portfolio

Medtronic, a global leader in healthcare technology, has announced an expanded distribution agreement with Retia Medical to bring the Argos™* cardiac output monitor to hospitals across Western Europe †. The agreement expands the Acute Care & Monitoring (ACM) portfolio of Medtronic in Western Europe, strengthening its perioperative and critical care offering with advanced haemodynamic monitoring technology. Financial terms of the agreement were not disclosed.

The Argos™* cardiac output monitor provides clinicians with accurate haemodynamic data and reliable trending,[1] and is designed to support informed decision-making in the care of high-risk surgical and critically ill adult patients. In the operating room and intensive care unit, circulatory shock—often presenting as hypotension—can progress rapidly if not identified early. Advanced haemodynamic monitoring plays an important role in detecting changes in cardiovascular status, enabling timely and individualised clinical response.[2,‡]

Clinical evidence suggests that pre-emptive haemodynamic intervention supported by advanced monitoring has been associated with 1–2-day shorter ICU stays[3], highlighting the potential value[3-5] of advanced haemodynamic monitoring in complex care environments.

"Our focus is on helping clinicians navigate complexity with greater clarity," said Marc De Martini, Western Europe commercial vice president of the Acute Care & Monitoring business, which is part of the Medical Surgical portfolio at Medtronic. "The Argos™* cardiac output monitor adds meaningful haemodynamic insight to our Acute Care & Monitoring portfolio and complements established technologies such as INVOS™ cerebral oximetry, supporting a more comprehensive view of patient status across perioperative and critical care environments. By bringing this technology to Western Europe, we are reinforcing our commitment to partner

with healthcare systems as they work to deliver high-quality care in an increasingly resource-constrained environment."

The Argos™* cardiac output monitor offers an advanced algorithm called Multi-Beat Analysis™* (MBA™*), developed at the Massachusetts Institute of Technology (MIT) and Michigan State University. Unlike other monitors that analyse only one beat at a time, the MBA™* algorithm analyses multiple heartbeats from the blood pressure signal to model a patient's vascular resistance directly. It provides accurate hemodynamic data on ten comprehensive parameters even during changes in vasomotor tone, low cardiac output, and arrhythmia.[1]

"Medtronic is an ideal partner for Retia Medical as we expand access to the Argos™* cardiac output monitor in Western Europe," said Marc Zemel, chief executive officer of Retia Medical. "With a robust portfolio, deep customer relationships, and leadership in advancing acute care and monitoring technologies, Medtronic is uniquely positioned to help bring the benefits of our innovative solution to clinicians and patients across Western Europe. We look forward to working together to help to set a new standard in hemodynamic monitoring."

The Argos™* cardiac output monitor leverages the patient's existing arterial line, eliminating the need for a proprietary transducer by connecting through a single reusable cable to a standard radial blood pressure transducer. The monitor is easy to use, features an intuitive multi-touch screen interface, and can be fully operational quickly.[6] In addition, there is no need for costly disposable accessories to connect. For more information about the Argos™* cardiac output monitor visit medtronic.co.uk/argos.

About Retia Medical

Headquartered in White Plains, NY, Retia Medical Systems, Inc. is a venture-backed developer and provider of advanced algorithms including AI-based approaches for patient monitoring and management. Retia's mission is to provide accurate data and insights to aid surveillance, diagnosis and management of high-risk surgical and critically ill patients to improve outcomes. Retia Medical's Argos™* Monitor, with its Multi-Beat Analysis (MBA®) algorithm, provides consistently accurate hemodynamic measurements for critically ill adult patients, enabling clinicians to make more informed, data-driven decisions to improve end-organ function. Additionally, the Argos™ system is unique in its class by not requiring costly disposables to monitor each patient. The Argos™ uses a single cable connection and takes less than 1 minute to start monitoring. Learn more at www.retiamedical.com and follow Retia Medical on LinkedIn.

About Medtronic

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Argos™* cardiac output monitor is manufactured by Retia Medical and distributed by Medtronic.

Patient Monitoring products should not be used as the sole basis for diagnosis or therapy and are intended only as an adjunct in

patient assessment.

*Third party brands are trademarks of their respective owners.

Argos, Multi-Beat Analysis, and MBA are trademarks or registered trademarks of Retia Medical Systems, Inc.

References:
†The Medtronic distribution agreement excludes Belgium, Netherlands and Israel.

‡Claim based on study results of like technology.

1. Kee A, Kirchhoff B, Grigsby J, et al. Prospective Evaluation of a Multibeat Analysis Cardiac Index Estimation in Patients With Cardiogenic Shock. J Cardiothorac Vasc Anesth. 2023;37(8):1377-1381. doi:10.1053/j.jvca.2023.04.003
2. Bose EL, Hravnak M, Pinsky MR. The interface between monitoring and physiology at the bedside. Crit Care Clin. 2015;31(1):1-24.
3. Dave C, Shen J, Chaudhuri D, et al. Dynamic Assessment of Fluid Responsiveness in Surgical ICU Patients Through Stroke Volume Variation is Associated With Decreased Length of Stay and Costs: A Systematic Review and Meta-Analysis. Journal of Intensive Care Medicine. 2020;35(1):14-23.
4. Benes J, Giglio M, Brienza N, Michard F. The effects of goal-directed fluid therapy based on dynamic parameters on post-surgical outcome: a meta-analysis of randomized controlled trials. Crit Care. 2014;18(5):584. Published 2014 Oct 28. doi:10.1186/s13054-014-0584-z
5. Pinksy MR, Cecconi M, Chew MS, et al. Effective hemodynamic monitoring. Critical Care. 2022; 26(1):924.
6. Based on internal testing held by manufacturer.

Contacts:
Maria Trenzado
Public Relations
+34-653-30-4720

Ingrid Goldberg
Investor Relations
+1-763-505-2696

https://news.medtronic.com/Medtronic-expands-its-Acute-Care-Monitoring-portfolio-in-Europe-with-a-distribution-agreement-for-the-Argos-TM-cardiac-output-monitor